middle.news
Immuron Reports 6% Revenue Growth and FDA Approval in FY26
8:39am on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
Immuron Reports 6% Revenue Growth and FDA Approval in FY26
8:39am on Friday 28th of August, 2026 AEST
Key Points
Global sales up 6% to $7.7 million
Net loss narrowed by $1.4 million to $3.8 million
FDA approves IMM-529 IND for clinical development
New US Department of Defense subaward secured
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immuron (ASX:IMC)
OPEN ARTICLE